drugset
drugset / Trial / NCT01652092

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT01652092 ↗

Active not recruiting 57 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.

Timeline

Start
2012-09-04
Primary completion
2025-12-30
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody 0.2 mg/kg Intravenous
Subject Alemtuzumab Monoclonal antibody 0.3 mg/kg Intravenous
Subject Busulfan Small molecule 0.8 mg/kg Intravenous
Subject Busulfan Small molecule 1.1 mg/kg Intravenous
Subject Cyclophosphamide Other / unclassified 50 mg/kg Intravenous
Subject Fludarabine Small molecule 1.33 mg/kg Intravenous
Subject Fludarabine Small molecule 30 mg/m2 Intravenous
Subject Fludarabine Small molecule 40 mg/m2 Intravenous
Subject Melphalan Small molecule 140 mg/m2 Intravenous
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule — —

Indications

Chediak-Higashi syndrome Griscelli syndrome Langerhans cell histiocytosis Omenn syndrome Wiskott-Aldrich syndrome X-linked lymphoproliferative syndrome chronic granulomatous disease common variable immunodeficiency hyper-IgM syndrome reticular dysgenesis